ArticleCancer control : journal of the Moffitt Cancer Center
Socioeconomic Disparities in Multiple Myeloma Survival in New South Wales Australia: A Population-Based Cohort Study.
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionAustralia has one of the highest incidence rates of multiple myeloma (MM) globally, and this burden is projected to increase significantly in the coming decades. Survival has improved over time, but it is not clear how this differs by socioeconomic group. Here, we used population-based data to evaluate survival differences by socioeconomic group and other prognostic factors of individuals with MM in Australia.MethodsThis retrospective study included individuals diagnosed with primary MM between 2008 and 2019, as recorded in the New South Wales Cancer Registry, with survival follow-up to 2020. The identified individuals with primary MM were classified into 3 socioeconomic groups (low, medium, high) based on their residential location at diagnosis. Competing-risk modelling was used to estimate sub-hazard ratios (SHR) for socioeconomic group adjusting for potential prognostic factors, including age at diagnosis, sex, year of diagnosis, remoteness areas, autologous stem cell transplantation (ASCT) use, and hospital type.ResultsOverall, 6,030 individuals were included in the study. The 5-year cumulative incidence of death due to MM was higher (p<0.0001) in low and medium socioeconomic groups (0.42 and 0.39), compared with the high socioeconomic group (0.34). Individuals in the high socioeconomic group were more likely to receive ASCT and to receive care at public principal referral/private hospitals. Compared to the high socioeconomic group, the excess risk of dying was higher (p<0.0001) in low (SHR=1.27, 95% CI: 1.14-1.42) and medium (SHR=1.20, 95% CI: 1.08-1.33) socioeconomic groups, but not statistically different (p=0.13) when other prognostic factors were considered.ConclusionSurvival disparity by socioeconomic groups among individuals with MM in Australia is largely accounted for by known prognostic factors, especially ASCT receipt and hospital type. Existing disparities suggest that a comprehensive evaluation of access to and availability of MM treatment, including identification of potential barriers to treatment receipt, is urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.